A focused pipeline for rare disease.
MGAM advances three biopharmaceutical programs across rare neurological, metabolic, and neurodevelopmental diseases.
Life Sciences — Active pipeline
Rare-disease programs centered on defined patient populations, focused development strategies, and substantial unmet need.
| Program | Indication | Candidate | Regulatory milestone |
|---|---|---|---|
| MGAM-001 | Rare neurodevelopmental disorder | Candidate undisclosed | ODD request under FDA review |
| MGAM-002 | Rare metabolic disease | Candidate undisclosed | ODD request under FDA review |
| MGAM-003Classic PMD | Classic Pelizaeus-Merzbacher diseaseRare pediatric disease | Clemastine fumarate | Rare Pediatric Disease Designation granted |